Table 1_BRCA genetic testing and treatment patterns for patients with HER2-negative early-

A retrospective cohort study of 3,741 patients diagnosed with clinical stage I-III HER2-negative early-stage breast cancer from 1-Jan-2022 to 22-Jan-2024, using a longitudinal, real-world dataset from US community healthcare systems. The dataset, authored by Kathryn E. Mishkin and last updated in March 2026, describes BRCAm testing patterns, prevalence, and subsequent therapy selection.

Use Cases

• Analyzing BRCA testing rates over time based on the reported 51% in 2022 and 56% in 2023.
• Comparing treatment regimens (e.g., mastectomy rates, adjuvant therapy types) between BRCA-mutated and non-mutated patient groups.
• Investigating testing timelines based on the reported percentages of tests conducted before diagnosis, at/before surgery, and after surgery.
• Studying the adoption of adjuvant olaparib based on the count of 18 patients who received it.

Strengths

• Includes 3,741 patient records with a median follow-up of 20.2 months.
• Provides specific, real-world metrics on testing rates, prevalence (5% BRCA-mutated), and treatment patterns.
• Focuses on a recent and relevant time period (2022-2024) following a key drug approval.

Limitations

• Row count and column-level documentation are unknown, which may limit suitability assessment.
• Data may reflect geographic and source bias inherent to the specific US community healthcare systems used.
• Description metadata is limited; actual data quality and structure require manual inspection after download.

Provenance

Source

figshare, authored by Kathryn E. Mishkin.

Collection Method

Retrospective cohort study using a longitudinal, real-world dataset from US community healthcare systems.

Time Range

1-Jan-2022 to 22-Jan-2024 (diagnosis period).

Freshness

Last updated 2026-03-18 07:45:07; freshness should be verified.

Geography

United States (community healthcare setting).